Introduction
============

Hypopharyngeal carcinoma is a primary malignant tumor of the hypopharynx, accounting for 3-5% of the malignancies in the upper aerodigestive tract. Early diagnosis of hypopharyngeal cancer is hard because the early stages of hypopharyngeal carcinoma have no specific symptoms. Studies have reported that 60-80% of these patients had ipsilateral lymph node metastases and ≤40% of these patients have contralateral occult lymph node tumor deposits ([@b1-ijmm-43-01-0127]-[@b3-ijmm-43-01-0127]). Thus, the majority of patients with hypopharyngeal cancer have a poor prognosis and low survival rate ([@b4-ijmm-43-01-0127]). Therefore, identifying early stage indicators or biomarkers to improve patient survival is urgent.

Unlike normal linear RNA, the 3′ and 5′ ends of circular RNAs (circRNAs) are linked by covalent bonds and lack polarities or polyadenylated tails, thereby rendering them stable in tissues, serum and urine ([@b5-ijmm-43-01-0127]). Owing to this characteristic, the potential of circRNAs as biomarkers for human cancer has attracted significant focus. In addition, circRNAs are widely involved in cancer; ciRS-7 in HeLa cells ([@b6-ijmm-43-01-0127]), Hsa\_ circ_001569 in colorectal cancer ([@b7-ijmm-43-01-0127]), circHIPK3 in several types of cancer ([@b8-ijmm-43-01-0127]), f-circM9, f-circPR in hematological malignancy ([@b9-ijmm-43-01-0127]), and circTCF25 in urinary bladder carcinoma ([@b10-ijmm-43-01-0127]). Previous studies have demonstrated that the main function of circRNAs is that they can function as a microRNA (miRNA) sponge, binding to miRNAs and regulating them and their downstream gene targets, through a competing endogenous (ce) RNA mechanism ([@b11-ijmm-43-01-0127]).

The present study comprehensively investigated the expression profile of circRNAs in HCa patients. The results identified a circRNA signature in HCa and suggested that a core miRNA-ceRNA network, regulating both the ErbB and Hippo signaling pathways, may have important roles in HCa progression.

Materials and methods
=====================

Patients and specimens
----------------------

The study included three patients with HCa who underwent partial or radical cystectomies at the First Affiliated Hospital of Kunming Medical University (Kunming, China); samples were collected from March 2017 to October 2017. All three patients were male and their ages were 44, 54 and 56. Following surgery, the matched specimens were immediately preserved in liquid nitrogen until use. All patient samples were confirmed by pathological examination and none of the patients received neoadjuvant therapy. The study was approved by the Second Department of Otolaryngology Head and Neck Surgery of the First Affiliated Hospital of Kunming Medical University (Kunming, China). Written informed consent was obtained from all the participants in the study.

Total RNA isolation and quality control
---------------------------------------

Total RNA was isolated from samples using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) following the manufacturer's protocol. The quantity and quality of total RNA samples were measured using NanoDrop ND-1000 (Thermo Fisher Scientific, Inc.). RNA integrity was assessed and confirmed via electrophoresis using denaturing agarose gels. Isolated RNA samples were stored at −80°C prior to use.

Library preparation and sequencing
----------------------------------

Total RNA from three matched HCa samples and adjacent normal tissues were treated with Epicenter Ribo-Zero rRNA Removal kit (Illumina, Inc., San Diego, CA, USA) and RNase R (Epicenter; Illumina, Inc.) to remove ribosomal and linear RNA. Then, the RNA-seq libraries were constructed using TruSeq Stranded Total RNA HT/LT Sample Prep kit (Illumina, Inc.). Sequencing was determined on Illumina Hiseq 2500 instrument with 2×150 bp paired reads.

Computational analysis of circRNAs
----------------------------------

The clean reads were obtained after the raw reads were preprocessed with the FastQC quality control tool ([@b12-ijmm-43-01-0127]). CircRNAs were identified using CIRI (v.1.2) pipeline with default parameters ([@b13-ijmm-43-01-0127]). Genomic circRNAs were mapped to the human reference genome (GRCh37) by BWA ([@b14-ijmm-43-01-0127]). All circRNAs were annotated for circRNA-hosting genes with the application of GENCODE v24 ([@b15-ijmm-43-01-0127]). The identified circRNAs were converted to circRNA ID with web server circBase ([@b16-ijmm-43-01-0127]).

Principal component analysis (PCA)
----------------------------------

PCA was performed as previously described ([@b17-ijmm-43-01-0127]). A total of 4,634 distinct circRNAs with non-zero raw counts across the six samples were isolated and expressions of circRNAs were normalized with the reads per Million mapped reads (RPM) method and the expression matrix (each row represented a gene, each column represented a sample) were used for PCA. The prcomp package from R was used to perform PCA and the default parameters were used ([@b18-ijmm-43-01-0127]). The ggplot2 package from R was used to draw the scatter plot ([@b19-ijmm-43-01-0127]).

Normalization and differential expression analysis of circRNAs
--------------------------------------------------------------

Two steps were performed to normalize circRNA expression for depth. Firstly, the total back-spliced reads in a sample were counted and that number was divided by 1,000,000. This resulted in the 'per million' scaling factor. Secondly, the read counts were divided by the 'per million' scaling factor. This method normalized for sequencing depth, giving RPM. CircRNAs were isolated with RPM\>0 across 6 samples and Mann-Whitney U test ([@b20-ijmm-43-01-0127]) (paired=T) followed by Benjamini-Hochberg multiple testing correction ([@b21-ijmm-43-01-0127]) were applied to identify the differentially expressed (DE) circRNAs. FDR\<0.05 and a fold change of \>2.0 or \<0.5 were the selection criteria for significant DE circRNAs.

Functional enrichment analysis
------------------------------

Gene ontology (GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted with web server DAVID 6.8 ([@b22-ijmm-43-01-0127]). P\<0.05 was considered as statistically significant.

CeRNA network
-------------

The top 20 upregulated circRNAs and the top 20 downregulated circRNAs were used to survey miRNA targets with the web tool CircInteractome ([@b23-ijmm-43-01-0127]). Specifically, CircInteractome downloads the mature sequences of circRNAs from the UCSC browser mirror (<http://genome.mdc-berlin.de>) ([@b24-ijmm-43-01-0127]) and predicts miRNAs that target circRNA by surveying for 7-mer or 8-mer complementarity to the seed region, as well as the 3′end of each miRNA using the TargetScan algorithm ([@b25-ijmm-43-01-0127]). The complete miRNA list and sequences were taken from the miRBase (<http://www.mirbase.org/>) ([@b16-ijmm-43-01-0127]). miRNA downstream targets were isolated with mirPath 3.0 ([@b26-ijmm-43-01-0127]) which was also used for miRNA KEGG pathway analysis. The ceRNA network was displayed by Cytoscape (v3.5.1) ([@b27-ijmm-43-01-0127]).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------------------

Total RNA was extracted from pooled normal and tumor tissue samples using TRIzol (Thermo Fisher Scientific, Inc.), and 1 *µ*g of total RNA was reverse transcribed into first-strand cDNA using a PrimeScript RT Reagent kit (Takara Bio, Inc., Otsu, Japan), according to the manufacturer's protocols. qPCR was performed with a SYBR-Green real-time PCR kit (Thermo Fisher Scientific, Inc.) using the ABI StepOnePlus Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). CircRNAs were analyzed with 18s rRNA as the internal standard and miRNA was analyzed with U6 as the internal standard. The reactions were prepared as follows: 7.5 *µ*l SYBR Premixm Ex Taq II, 0.25 *µ*l ROX Reference Dye II, 0.125 *µ*l forward primer, 0.125 *µ*l reverse primer, 5 *µ*l RNase-free water, and 2 *µ*l cDNA. The thermocycling conditions were: one step at 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec, and a final step of 95°C for 15 sec, 60°C for 15 sec and 95°C for 15 sec. Primer sequences are listed in [Table I](#tI-ijmm-43-01-0127){ref-type="table"}; expression levels were quantified via the 2^−ΔΔCq^ method ([@b28-ijmm-43-01-0127]).

Expression analysis of miR-548c-3p
----------------------------------

Two methods were used to investigate the expression of miR-548c-3p among normal and tumor samples. The first was RT-qPCR, as detailed above. The second was in-silico analysis. The miRNA dataset of the esophageal carcinoma cohort from The Cancer Genome Atlas (TCGA) project ([@b29-ijmm-43-01-0127]) was exploited. There were 13 normal samples and 184 tumor samples in this dataset. Normalized miRNA expressions of miR-548c-3p were compared between normal and tumor samples. Mann-Whitney U test was applied to test the significance.

Survival analysis
-----------------

A Kaplan-Meier curve was used to examine the clinical relevance of miR-548c-3p levels in the patients' outcomes ([@b30-ijmm-43-01-0127]). Patients were separated into two groups according to the median expression of hsa-miR-548c-3p using TCGA clinical and expression dataset. Differences between groups were analyzed using log-rank test ([@b31-ijmm-43-01-0127]) and two-tailed P-values \<0.05 were considered statistically significant. Statistical analyses were performed using the survival package (version 2.39-5) in R (version 3.4.3).

Expression correlation of hsa-miR-548c-3p and its targeted genes
----------------------------------------------------------------

The miRNA and mRNA datasets of the esophageal carcinoma cohort from TCGA ([@b29-ijmm-43-01-0127]) were used for the correlation analysis. Common samples were isolated according to the sample barcodes. The Pearson correlation method was used to assess the expression association between hsa-miR-548c-3p and the targeted genes. Significance of association was determined by the R package cor.test (alternative='two.sided', method='pearson'). Then, P-values were corrected with Benjamini-Hochberg procedure for multiple testing.

Statistical analysis
--------------------

All statistical analyses were generated using R ([@b32-ijmm-43-01-0127]). The Pearson correlation method was used to assess the expression association. Significances of associations were determined by the R package cor.test. Mann-Whitney U test was used for comparisons between two groups. Benjamini-Hochberg procedure was applied for multiple testing. Log-rank test was used for Kaplan-Meier survival curves. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Identification of DE circRNAs in HCa
------------------------------------

To identify DE circRNAs in HCa, circRNA sequencing (Seq) was performed using three matched normal and HCa tissue samples, and an average of 90 million reads was achieved for each sample. A total of 4,634 distinct circRNAs with at least two unique back-spliced reads across six samples using CIRI pipeline ([@b13-ijmm-43-01-0127]) were identified and the expressions of circRNAs were normalized and represented by reads per million mapped reads (RPM) values. Genetic distances across 6 samples were evaluated using PCA ([Fig. 1A](#f1-ijmm-43-01-0127){ref-type="fig"}), and the normalized expression level (RPM) of circRNAs across the six samples is illustrated in [Fig. 1B](#f1-ijmm-43-01-0127){ref-type="fig"}. Following statistical analysis, 71 and 102 circRNAs were determined to be significantly upregulated and downregulated, respectively ([Table II](#tII-ijmm-43-01-0127){ref-type="table"}). The DE circRNAs between tumor and adjacent normal samples were presented in a heatmap ([Fig. 1C](#f1-ijmm-43-01-0127){ref-type="fig"}). To confirm the circRNA-Seq results, RT-qPCR was performed to assess the expression of 19 of the above DE circRNAs in both normal and tumor samples. The results confirmed that 12 of them were consistently upregulated or downregulated with the circRNA-Seq results ([Fig. 2](#f2-ijmm-43-01-0127){ref-type="fig"}).

Next, the distribution of circRNAs in different DNA elements and chromosomes was examined. The bar diagram of [Fig. 3A](#f3-ijmm-43-01-0127){ref-type="fig"} demonstrates the % of back-spliced junction reads on intron, intergenic, and exon areas. The majority of circRNAs belonged to exonic, followed by intronic and intergenic elements ([Fig. 3B](#f3-ijmm-43-01-0127){ref-type="fig"}). These dysregulated circRNAs are widely distributed in all chromosomes, including sex chromosomes X ([Fig. 3C](#f3-ijmm-43-01-0127){ref-type="fig"}).

Functional enrichment analysis of genes producing DE circRNAs
-------------------------------------------------------------

To reveal the dysregulated pathways underlying HCa, first KEGG pathway enrichment analyses were performed for genes that matched DE circRNAs. The results demonstrated that genes containing downregulated circRNAs were enriched in endocytosis, ubiquitin-mediated proteolysis, and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways ([Fig. 4A](#f4-ijmm-43-01-0127){ref-type="fig"}), whereas there were no KEGG pathways enriched with genes producing upregulated circRNAs.

Next, GO term enrichment analyies was performed for genes that produced aberrantly expressed circRNAs. Biological processes, such as the establishment of spindle orientation, response to fungicide, positive regulation of transcription, cell division were significantly enriched ([Fig. 4B](#f4-ijmm-43-01-0127){ref-type="fig"}), whereas genes producing downregulated circRNAs were related to autophagy, mitochondrion organization actin cytoskeleton organization, membrane fission, and cell-cell adhesion pathways ([Fig. 4C](#f4-ijmm-43-01-0127){ref-type="fig"}). These results suggested that multiple pathways may contribute to HCa pathogenesis and progression.

CircRNAs regulate the ErbB and Hippo pathways through a miRNA-CeRNA network
---------------------------------------------------------------------------

The role of circRNAs as a miRNA sponge is the main mechanism of circRNA function in tumor cells ([@b11-ijmm-43-01-0127],[@b33-ijmm-43-01-0127]). Therefore, we further investigated the roles of circRNAs in HCa progression through establishing a ceRNA network. Firstly, the top 20 upregulated and top 20 downregulated circRNAs were isolated and were converted to circRNA ID using circBase database ([@b34-ijmm-43-01-0127]). Secondly, miRNAs targeting DE-circRNAs were isolated with the web server CircInteractome ([@b23-ijmm-43-01-0127]). Specifically, CircInteractome downloaded the mature sequences of all of the reported circRNAs from the UCSC browser, then to characterize miRNA-circRNA interactions, CircInteractome incorporated the ability to search using the TargetScan algorithm, which predicts miRNAs that target circRNA by surveying for 7-mer or 8-mer complementarity to the seed region as well as the 3′end of each miRNA ([@b23-ijmm-43-01-0127]). A total of 191 and 182 miRNAs were putatively identified as the targets of upregulated and downregulated circRNAs, respectively. Networks consisted of circRNAs and miRNAs were displayed using Cytoscape software ([@b27-ijmm-43-01-0127]). The results demonstrated extensive interactions between miRNAs and upregulated ([Fig. 5A](#f5-ijmm-43-01-0127){ref-type="fig"}), and downregulated circRNAs ([Fig. 5B](#f5-ijmm-43-01-0127){ref-type="fig"}). Then, KEGG pathway enrichment analysis was performed for the miRNAs targeted by the top 40 DE circRNAs, in order to explore the altered biological processes using mirPath 3.0 ([@b26-ijmm-43-01-0127]). Genes targeted by miRNAs were significantly enriched in multiple signaling pathways, including the ErbB, the Hippo, the Ras, the transforming growth factor (TGF)-β, the phosphoinositide 3-kinase/AKT serine/threonine kinase and the Wnt signaling pathways ([Fig. 5C](#f5-ijmm-43-01-0127){ref-type="fig"}).

To get further insight into the function of circRNAs in the ErbB and Hippo signaling pathways, miRNA-ceRNA networks were constructed corresponding to the two pathways using Cytoscape. For the miRNA-ceRNA network regulating the ErbB pathway, there were 33 circRNAs, 43 miRNAs and 74 ErbB pathway genes ([Fig. 6A](#f6-ijmm-43-01-0127){ref-type="fig"}). In the ErbB miRNA-ceRNA network, we isolated a subnetwork consisting of circRNAs (hsa_circ_0008287 and hsa_circ_0005027), miRNAs (hsa-miR-548c-3p) and 38 ErbB pathway genes which had the most interaction between miRNAs and targeted genes ([Fig. 6B](#f6-ijmm-43-01-0127){ref-type="fig"}). Hsa_circ_0008287 and hsa_circ_0005027 were significantly downregulated in tumor samples compared with normal ([Figs. 2](#f2-ijmm-43-01-0127){ref-type="fig"} and [6C](#f6-ijmm-43-01-0127){ref-type="fig"}). In a similar manner, the miRNA-ceRNA network regulating the Hippo pathway was constructed, consisting of 33 circRNAs, 43 miRNAs and 110 Hippo pathway genes ([Fig. 7A](#f7-ijmm-43-01-0127){ref-type="fig"}). In the Hippo miRNA-ceRNA network, we also isolated a subnetwork consisting of circRNAs (hsa_circ_0008287 and hsa_circ_0005027), miRNAs (hsa-miR-548c-3p) and 61 Hippo pathway genes, which had the most interaction between miRNAs and targeted genes ([Fig. 7B](#f7-ijmm-43-01-0127){ref-type="fig"}).

To further investigate the important role of this subnet-work in tumor progression, the miRNA and mRNA datasets of the esophageal carcinoma cohort from TCGA ([@b29-ijmm-43-01-0127]) were exploited. The esophageal carcinoma cohort contains 13 normal samples and 184 tumor samples. In this cohort, the miRNA hsa-miR-548c-3p expression between normal and tumor samples was detected, and its clinical relevance to patient survival was analyzed. The results suggested that hsa-miR-548c-3p was highly expressed in tumor samples compared with normal samples ([Fig. 8A and B](#f8-ijmm-43-01-0127){ref-type="fig"}), and its high expression was significantly associated with lower survival in patients with esophageal carcinoma ([Fig. 8C](#f8-ijmm-43-01-0127){ref-type="fig"}). These findings suggested that hsa-miR-548c-3p is an oncogenic miRNA, which is consistent with the hypothesis that in tumor samples circRNAs were downregulated resulting in more oncogenic hsa-miR-548c-3p being released, and highly expressed hsa-miR-548c-3p may promote HCa progression through downstream target genes. To confirm the negative regulation of hsa-miR-548c-3p on the ErbB and Hippo pathway genes, the expression correlation of hsa-miR-548c-3p and its targeted genes were also analyzed. Many of the targeted genes were negatively correlated with hsa-miR-548c-3p levels, which supported a negative regulatory role of hsa-miR-548c-3p on the ErbB and Hippo pathways ([Table III](#tIII-ijmm-43-01-0127){ref-type="table"}). The present results demonstrated that circRNAs regulate HCa progression through multiple pathways and identifying a miRNA-ceRNA network that regulated the ErbB and Hippo signaling pathways.

Discussion
==========

HCa is clinically difficult to diagnose and has a poor prognosis, therefore, identifying early stage molecular biomarkers has become urgent. CircRNAs, which are stable and easier to extract and detect, are considered ideal candidates for early-stage biomarkers. This is the first report on the expression profile of circRNAs in HCa. In the present study, a number of aberrantly expressed circRNAs in HCa samples were identified. Pathway enrichment results revealed that circRNAs may regulate HCa progression through multiple signaling pathways, especially the ErbB and Hippo signaling pathways. These results provided several potential biomarkers and therapeutic targets for HCa.

The ceRNA hypothesis was described as a way that RNAs communicate with each other, via competing for binding to miRNAs and regulating the expression of each other to construct a complex post-transcriptional regulatory network ([@b35-ijmm-43-01-0127],[@b36-ijmm-43-01-0127]). mRNAs and long non-coding (lnc) RNAs may all serve as ceRNAs ([@b37-ijmm-43-01-0127]). It has been demonstrated that circRNAs can also function as miRNA sponges ([@b6-ijmm-43-01-0127],[@b11-ijmm-43-01-0127]). The present study demonstrated that aberrantly expressed circRNAs have extensive interactions with miRNAs, and those miRNAs exerted their effect on multiple cancer-related pathways. These data indicated that the circRNA-associated ceRNA network may have crucial roles in HCa progression.

The activation of ErbB oncogenes has been described in various types of human tumors, including hypopharynx carcinomas, and it has been correlated with a poor prognosis. For example, one study describing the molecular alterations in hypopharynx carcinomas demonstrated that ErbB1 was amplified in 29% of patients with hypopharyngeal squamous cell carcinomas ([@b38-ijmm-43-01-0127]). In addition, ErbB1 amplification is correlated with a hypopharyngeal primary site ([@b39-ijmm-43-01-0127]). Another study reported that v-erbB stained positively in 62.5% of hypopharyngeal squamous cell carcinomas samples but negatively in normal mucosa ([@b40-ijmm-43-01-0127]). The present ceRNA network analysis demonstrated that a circRNA (hsa_circ_0008287 and hsa_circ_0005027)/miRNA (hsa-miR-548c-3p) axis may have important roles in ErbB-mediated tumor progression ([Fig. 6](#f6-ijmm-43-01-0127){ref-type="fig"}).

Another pathway that is likely to be associated with hypopharynx carcinomas is the Hippo signaling pathway. The Hippo pathway has generated considerable interest in recent years because of its involvement in several key hallmarks of cancer progression and metastasis ([@b41-ijmm-43-01-0127]). Regulation of Hippo signaling can be an attractive alternative strategy for cancer treatment ([@b42-ijmm-43-01-0127]-[@b44-ijmm-43-01-0127]). Previously, ACTL6A and p63 were demonstrated to cooperatively promote head and neck squamous cell carcinoma, through activation of the Hippo/Yes-associated protein 1 (YAP) pathway and YAP activation can predict poor patient survival ([@b45-ijmm-43-01-0127]). The present ceRNA network analysis demonstrated that a circRNA (hsa_circ_0008287 and hsa_circ_0005027)/miRNA (hsa-miR-548c-3p) axis may have important roles in Hippo-mediated tumor progression ([Fig. 7](#f7-ijmm-43-01-0127){ref-type="fig"}).

Extensive evidence has suggested that miRNAs have important roles in breast cancer. The miR-548 family has been demonstrated to be involved in the pathogenesis of several cancers. For example, miR-548-3p was significantly downregulated in breast cancer and overexpression of miR-548-3p inhibited the proliferation and promoted the apoptosis of breast cancer cells ([@b46-ijmm-43-01-0127]). Overexpression of miR-548c-3p was also confirmed in prostate epithelial stem cells and in castration-resistant prostate cancer cells ([@b45-ijmm-43-01-0127]). Overexpression of miR-548c-3p in differentiated cells induced stem-like properties and radio-resistance ([@b45-ijmm-43-01-0127]). Re-analyses of published studies further revealed that miR-548c-3p is significantly overexpressed in castration-resistant prostate cancer cells and is associated with poor recurrence-free survival, suggesting that miR-548c-3p is a functional biomarker for prostate cancer aggressiveness ([@b47-ijmm-43-01-0127]). The present results demonstrated that miR-548c-3p may have important roles in HCa progression through modulating the ErbB and Hippo pathways. Due to the crucial roles of miR-548c-3p in multiple types of cancer, development of novel gene therapies based on miR-548c-3p might be encouraged.

Taken together, the present study indicated that hsa\_ circ_0008287 and hsa_circ_0005027 were downregulated in HCa and competitively bound miR-548c-3p with ErbB and Hippo signaling pathway genes. Further studies are warranted on the roles of hsa_circ_0008287, hsa_circ_0005027, and miR-548c-3p as potential diagnostic biomarkers and therapeutic targets for HCa.
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![Identification of differentially expressed circRNAs in hypopharyngeal cancer. (A) PC analysis of three tumor samples and three normal samples using circRNA profiles. (B) Boxplot showing the log2 transformed back-spliced junction counts across adjacent normal and cancerous samples. (C) Heatmap of relative expression of differentially expressed circRNAs in adjacent normal and cancerous samples. circRNAs, circular RNAs; PC, principal component; N, normal; T, tumor.](IJMM-43-01-0127-g00){#f1-ijmm-43-01-0127}

![Reverse transcription-quantitative polymerase chain reaction analysis. Twelve of 19 circRNAs were demonstrated to be consistently regulated with the circRNA-sequencing results. circRNAs, circular RNAs.](IJMM-43-01-0127-g01){#f2-ijmm-43-01-0127}

![Distribution of circRNAs in different DNA elements and chromosomes. (A) Bar diagram showing the % of back-spliced junction reads of circRNAs on genome elements. (B) Distribution of upregulated and downregulated circRNAs according to genome elements. (C) Distribution of numbers of differentially expressed circRNAs across the 23 chromosomes. circRNAs, circular RNAs; chr, chromosome.](IJMM-43-01-0127-g02){#f3-ijmm-43-01-0127}

![GO and KEGG pathway enrichment analyses. (A) KEGG pathway enrichment analysis of the genes that produced downregulated circRNAs. (B) GO enrichment analyses of genes that produced upregulated and (C) downregulated circRNAs. The blue bars denote the biological processes of genes producing downregulated circRNAs, while the orange bars denote the biological processes of genes producing upregulated circRNAs. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; circRNAs, circular RNAs.](IJMM-43-01-0127-g03){#f4-ijmm-43-01-0127}

![miRNA-ceRNA network. (A) Upregulated circRNAs/miRNAs ceRNA network. (B) Downregulated circRNAs/miRNAs ceRNA network. The red nodes represent circRNAs and the green nodes represent miRNAs. (C) KEGG pathway enrichment analysis of miRNAs. miRNA, microRNA; ceRNA, competing endogenous RNA; circRNAs, circular RNAs; KEGG, Kyoto Encyclopedia of Genes and Genomes.](IJMM-43-01-0127-g04){#f5-ijmm-43-01-0127}

![Involvement of circRNAs in the ErbB signaling pathway. (A) miRNA-ceRNA network of the ErbB signaling pathway. (B) Subnetwork consisting of circRNAs (hsa_circ_0008287 and hsa_circ_0005027)/miRNAs (hsa-miR-548c-3p) and ErbB pathway genes. (C) hsa_circ_0008287 and hsa_circ_0005027 were downregulated in tumor samples (circRNA-Sequencing results). circRNAs, circular RNAs; miRNA, microRNA; ceRNA, competing endogenous RNA.](IJMM-43-01-0127-g05){#f6-ijmm-43-01-0127}

![Involvement of circRNAs in the Hippo signaling pathway. (A) miRNA-ceRNA network of Hippo signaling pathway. (B) Subnetwork consisting of circRNAs (hsa_circ_0008287 and hsa_circ_0005027)/miRNAs (hsa-miR-548c-3p) and Hippo pathway genes. circRNAs, circular RNAs; miRNA, microRNA; ceRNA, competing endogenous RNA.](IJMM-43-01-0127-g06){#f7-ijmm-43-01-0127}

![hsa-miR-548c-3p expression in esophageal carcinoma and its association to patient survival. (A) Expression of hsa-miR-548c-3p between normal and tumor samples from patients with hypopharyngeal cancer, by reverse transcription-quantitative polymerase chain reaction analysis. Three technical replicates were used. (B) Expression of hsa-miR-548c-3p between normal and tumor samples of esophageal carcinoma, by in-silico analysis. The miRNA dataset of the esophageal carcinoma cohort from The Cancer Genome Atlas project was used for the analysis. (C) Kaplan-Meier plot of overall survival in patients with high or low expression of hsa-miR-548c-3p. miRNA, microRNA.](IJMM-43-01-0127-g07){#f8-ijmm-43-01-0127}

###### 

Primer sequences used for reverse transcription-quantitative polymerase chain reaction analysis.

  Gene               Forward primer (5′-3′)   Reverse primer (5′-3′)
  ------------------ ------------------------ ------------------------
  hsa_circ_0004670   GCTCCCAAGCAAAAGAGAAG     CTGCTTTGTGCTTCCGTATTC
  hsa_circ_0005703   TGGAGGAGAGGATCGAGTTC     GTTCTGGATGGTCTGCTTGG
  hsa_circ_0003214   TGTGTTTGGAACTGCTACCG     ATCAGCCAGGGCACTCAATA
  hsa_circ_0003146   CAACGACCTGGTGAAGAGG      GTCCGAGATCTCCAGCTTGT
  hsa_circ_0002059   GCCGAGTTAATGGTGGGTTT     ACCAAATTCAGCCAGAATGC
  hsa_circ_0002617   TTCCCCAGGAGTGTCAAGAT     TGGCAAAGATGAAAAGCTGA
  hsa_circ_0000660   CTTCCAGTGGGAATCCACAT     AGACATTCTTCCCTTCCAACAA
  hsa_circ_0054309   CTCTCAGCATGGGACCTTTT     CGATTTGGTTCTCCCATATCA
  hsa_circ_0003279   CTCTGTGCACGACTCTCAGG     TCCCTTCTTCGCTCTTCTCA
  hsa_circ_0000239   GAATGTTCAAATTGCTGCCATA   CCAGCAGCCCAACAATTACT
  hsa_circ_0091382   CTGCAGGGTCTGTTTTTACCA    CCCATCCAGATCAAGAGAGC
  hsa_circ_0004811   GGATCCAAAGGCACGTTTTA     AGAACTTCAGGCGCCAAGTA
  hsa_circ_0007480   GTTGGAGGAAGGGAAAGAGC     ATGGCCACATCCCTAAATGT
  hsa_circ_0013084   GGATGCTGCAAAAACGAGA      TGGGTTGTTTATACGACTTGGA
  hsa_circ_0008836   CCTTTTGAGCTGGGAAAACT     TCTGAAGGAATTCGGGACAG
  hsa_circ_0059060   GTGGAAGTGGAGAACCCAGA     ATGGGATGCTAGCCTTGAGA
  hsa_circ_0001312   TCAGTACTCTGGGGGAAAGG     GCTGGGACAGATGAAACCAT
  hsa_circ_0005027   TGTTGAGTTCGGCAGCATAC     ACACACCTCTGCAACCACAA
  hsa_circ_0008287   CCGAGCCACCTAAACAACAG     TCTGGGAGCGTCAGAAAGTT
  has-miR-548c-3p    CATTGGCATCTATTAGGTTG     GTATTAAGTTGGTGCAAAAG
  18s rRNA           ACCTGGTTGATCCTGCCAG      TCCAAGTAGGAGAGGAGCG
  U6                 GTGCTCGCTTCGGCAGCA       TGGAACGCTTCACGAATTTG

###### 

Differentially expressed circRNAs.

  circRNA ID (CIRI)               circRNA ID (circBase)   Adjusted P-value   FC                 Gene
  ------------------------------- ----------------------- ------------------ ------------------ -----------
  **chr16:21973780-21987564**     hsa_circ_0005690        0.022002929        9.346453412        UQCRC2
  **chr2:242343242-242357524**    hsa_circ_0004924        0.042106003        4.237176918        FARP2
  **chr7:72873865-72884813**      hsa_circ_0004670        0.003579475        4.136199328        BAZ1B
  **chr5:133871547-133887899**    hsa_circ_0005608        0.036132329        3.805820016        PHF15
  **chr22:41979962-41980607**     hsa_circ_0005703        0.030406606        3.76275756         PMM1
  **chr3:48019354-48040369**      hsa_circ_0005255        0.039183919        3.736266721        MAP4
  **chr12:27521194-27523163**     hsa_circ_0009009        0.01165016         3.553331882        ARNTL2
  **chr9:117399269-117401006**    hsa_circ_0002318        0.041159198        3.381349856 C      9orf91
  **chr1:165859440-165860559**    hsa_circ_0006758        0.041758958        3.367866028        UCK2
  **chr16:50321822-50322261**     hsa_circ_0000699        0.043912028        3.314878392        ADCY7
  **chr16:89484691-89497734**     hsa_circ_0000727        0.035411987        3.287797218        ANKRD11
  **chr8:98817580-98837381**      hsa_circ_0003214        0.018483558        3.272900498        LAPTM4B
  **chr19:48229068-48229481**     hsa_circ_0003146        0.006019062        3.268823068        EHD2
  **chr1:118003110-118045592**    hsa_circ_0002059        0.010572316        3.169435071        MAN1A2
  **chr14:92264128-92268765**     hsa_circ_0032969        0.040149042        3.130356466        TC2N
  **chr2:210968827-211019335**    hsa_circ_0002617        0.020968937        3.121028088 C      2orf67
  **chr15:94899365-94945248**     hsa_circ_0000660        0.032292149        3.092238966        MCTP2
  **chr2:43655238-43657441**      hsa_circ_0054309        0.002782953        3.091209609        THADA
  **chr2:110321942-110323436**    hsa_circ_0009020        0.03917314         3.05906561         SEPT10
  **chr19:2137009-2138713**       hsa_circ_0048344        0.040805597        3.048246172        AP3D1
  chr16:4311779-4312702           hsa_circ_0002439        0.046240525        2.987845154        TFAP4
  chr11:128993340-128997200       hsa_circ_0005027        0.001764073        2.945490868        ARHGAP32
  chr8:62460629-62479877          hsa_circ_0084604        0.018794062        2.926235997        ASPH
  chr3:155628480-155643155        hsa_circ_0008184        0.037854875        2.918397576        GMPS
  chr16:47531309-47581459         hsa_circ_0004791        0.048387875        2.9019822          PHKB
  chr20:35457456-35467844         hsa_circ_0060219        0.015622827        2.89815993         KIAA0889
  chr3:195101737-195112876        hsa_circ_0007331        0.048715375        2.872843159        ACAP2
  chr22:29517344-29521404         hsa_circ_0004547        0.044771757        2.802768657        KREMEN1
  chr2:122260742-122287901        hsa_circ_0002374        0.037227807        2.731455995        CLASP1
  chr3:128514202-128526514        hsa_circ_0006346        0.046003237        2.690296373        RAB7A
  chr4:83793096-83796975          hsa_circ_0003549        0.044620973        2.679827252        SEC31A
  chr12:1399017-1481143           hsa_circ_0024997        0.011882022        2.668639886        ERC1
  chr13:96409897-96416207         \#N/A                   0.005392448        2.660521497        \#N/A
  chr16:30715384-30715636         hsa_circ_0039076        0.030665031        2.628113834        SRCAP
  chr7:2400344-2404164            hsa_circ_0004869        0.033796697        2.611610945        EIF3B
  chr2:55209650-55214834          hsa_circ_0001006        0.045899911        2.579018715        RTN4
  chr12:42768664-42792796         hsa_circ_0003961        0.010866489        2.568055885        PPHLN1
  chr7:2404006-2406083            hsa_circ_0001671        0.022907729        2.551488457        EIF3B
  chr4:87685745-87689129          hsa_circ_0007948        0.022945704        2.547028768        PTPN13
  chr1:176085759-176105683        hsa_circ_0015373        0.029930944        2.536801963        RFWD2
  chr22:36737414-36745300         hsa_circ_0004470        5.2192E-05         2.529021894        MYH9
  chr2:32396355-32409407          hsa_circ_0053423        0.031086982        2.514457353        SLC30A6
  chr7:138951078-138957186        hsa_circ_0005594        0.027733961        2.504492053        UBN2
  chr9:95030455-95032265          hsa_circ_0008367        0.016513149        2.486273648        IARS
  chr7:65705311-65751696          hsa_circ_0006041        0.005514578        2.410252357        TPST1
  chr4:75040222-75067087          hsa_circ_0069981        0.032657959        2.370951734        MTHFD2L
  chr1:246021797-246093239        hsa_circ_0017289        0.010842885        2.366575966        SMYD3
  chr22:29090019-29091861         hsa_circ_0004811        0.001831625        2.363098777 C      HEK2
  chr16:3900297-3901010           hsa_circ_0007637        0.009154577        2.351311388 C      REBBP
  chr2:168920009-168931741        hsa_circ_0003279        0.000393597        2.342009076        STK39
  chr10:101728871-101731891       hsa_circ_0008393        0.049564434        2.328443205 D      NMBP
  chr9:140646782-140652463        hsa_circ_0001904        0.031745459        2.316860866        EHMT1
  chr22:46125304-46136418         hsa_circ_0001247        0.013526942        2.31185877         ATXN10
  chr14:23419522-23421892         hsa_circ_0005663        0.04538212         2.257072167        HAUS4
  chr12:122773035-122801402       \#N/A                   0.015647694        2.25006903         \#N/A
  chr4:3188323-3190820            \#N/A                   0.025850456        2.249708035        \#N/A
  chr3:172363412-172365904        hsa_circ_0007042        0.026989758        2.238835674        NCEH1
  chr2:10799297-10808849          hsa_circ_0008511        0.042758286        2.221921485        NOL10
  chr10:70696691-70703013         hsa_circ_0007097        0.040819924        2.219586601 DD     X50
  chrX:14868626-14877456          hsa_circ_0006971        0.009211245        2.215797457        FANCB
  chr1:23356961-23385660          hsa_circ_0007822        0.027240129        2.206406433        KDM1A
  chr20:13539654-13561628         hsa_circ_0002001        0.017808498        2.188222168        TASP1
  chr7:139741443-139757834        hsa_circ_0004684        0.026813206        2.168759032        PARP12
  chr7:72883846-72884813          hsa_circ_0003866        0.012904268        2.108744306        BAZ1B
  chr1:247319707-247323115        \#N/A                   0.039522611        2.102327859        \#N/A
  chr18:21644103-21663045         hsa_circ_0047270        0.020649137        2.07972359         TTC39C
  chr1:31532050-31532424          hsa_circ_0000045        0.009259898        2.078191163        PUM1
  chr2:63660878-63667005          hsa_circ_0003497        0.033526319        2.072706608        WDPCP
  chr10:128859931-128908618       hsa_circ_0020462        0.014021298        2.068064026 D      OCK1
  chr1:44773981-44804994          hsa_circ_0007693        0.022406409        2.066977275        ERI3
  chr7:99621041-99621930          hsa_circ_0001727        0.043987221        2.025308683        ZKSCAN1
  chr16:11873021-11876244         hsa_circ_0005420        0.045974717        0.499738449        ZC3H7A
  chr20:13539654-13561628         hsa_circ_0002001        0.03937226         0.497281358        TASP1
  chr3:43341245-43345284          hsa_circ_0004089        0.007985302        0.491228173        SNRK
  chrX:77084527-77086392          \#N/A                   0.020792399        0.489952895        \#N/A
  chr2:11905658-11907984          hsa_circ_0002229        0.013904514        0.48799699         LPIN1
  chr17:60111147-60112969         hsa_circ_0004273        0.010727519        0.487251947        MED13
  chr2:168920009-168986268        hsa_circ_0005882        0.018253559        0.481253188        STK39
  chr16:53532302-53534241         hsa_circ_0004072        0.021867418        0.480875236        AKTIP
  chr9:95030455-95032265          hsa_circ_0008367        0.024608207        0.480576493        IARS
  chr9:14146687-14179779          hsa_circ_0086376        0.025017135        0.480402794        NFIB
  chr12:122773035-122801402       \#N/A                   0.027697748        0.475833919        \#N/A
  chr20:35457456-35467844         hsa_circ_0060219        0.01965515         0.472752875        KIAA0889
  chr15:80412669-80415142         hsa_circ_0000643        0.019656594        0.47081423         ZFAND6
  chr4:144449020-144451679        \#N/A                   0.002041818        0.470785346        \#N/A
  chr15:62299506-62306191         hsa_circ_0000607        0.01862274         0.47022119         VPS13C
  chr21:40578033-40584633         \#N/A                   0.038815333        0.466807062        \#N/A
  chr10:128859931-128908618       hsa_circ_0020462        0.048526313        0.46671725 D       OCK1
  chr1:32381495-32385259          hsa_circ_0007364        0.012904962        0.464916349        PTP4A2
  chr2:148811959-148990964        \#N/A                   0.018584205        0.463574046        \#N/A
  chr8:37734626-37735069          hsa_circ_0001789        0.019846769        0.462223466        RAB11FIP1
  chr13:28748408-28752072         hsa_circ_0004372        0.023765765        0.461563778        PAN3
  chr18:9931806-9937063           hsa_circ_0006990        0.039623112        0.461171429        VAPA
  chr17:34910660-34923615         hsa_circ_0003930        0.021748331        0.458221861        GGNBP2
  chr22:46125304-46136418         hsa_circ_0001247        0.008045429        0.453521935        ATXN10
  chr2:206992520-206994966        hsa_circ_0002431        0.036437006        0.452588631        NDUFS1
  chr2:62100136-62103369          hsa_circ_0001018        0.029799501        0.451702188 CC     T4
  chr11:119144577-119145663       hsa_circ_0000362        0.025621724        0.450849769 C      BL
  chr4:39734978-39747430          \#N/A                   0.03460933         0.450272258        \#N/A
  chr22:29682911-29683123         hsa_circ_0008044        0.010096395        0.44308523         EWSR1
  chr14:21971315-21972024         hsa_circ_0000523        0.047512563        0.44023344         METTL3
  chr14:50615002-50616948         \#N/A                   0.013896814        0.437352627        \#N/A
  chr8:101232506-101243516        \#N/A                   0.028204026        0.430720792        \#N/A
  chr7:72883846-72884813          hsa_circ_0003866        0.004390368        0.424421462        BAZ1B
  chr18:46858233-46906128         hsa_circ_0002501        0.03573514         0.420126159 D      YM
  chr1:246784730-246797889        hsa_circ_0017311        0.028462249        0.41970008         CNST
  chr12:1399017-1481143           hsa_circ_0024997        0.040174171        0.417295868        ERC1
  chr12:27521194-27523163         hsa_circ_0009009        0.024711114        0.414722924        ARNTL2
  chr1:52959282-52975384          hsa_circ_0003632        0.045708435        0.414593811        ZCCHC11
  chr5:50055476-50059076          hsa_circ_0006787        0.018488474        0.412395338        PARP8
  chr3:179096128-179104417        hsa_circ_0002219        0.029224282        0.403006229        MFN1
  chr10:88203031-88206206         \#N/A                   0.022884862        0.399217754        \#N/A
  chr17:26490568-26499644         hsa_circ_0003638        0.013335258        0.397922038        NLK
  chr16:8952206-8953192           hsa_circ_0000669        0.000715169        0.397901388        CARHSP1
  chr2:186946056-186964557        \#N/A                   0.017444656        0.397798992        \#N/A
  chr11:85685750-85695016         hsa_circ_0006629        0.01991069         0.396956177        PICALM
  chr7:91980263-91991587          \#N/A                   0.035701238        0.389282593        \#N/A
  chr14:35519989-35522657         hsa_circ_0006424        0.04322634         0.387507944        FAM177A1
  chr12:42768664-42792796         hsa_circ_0003961        0.014465456        0.386034041        PPHLN1
  chr1:246021797-246093239        hsa_circ_0017289        0.011181456        0.38452595         SMYD3
  chr10:27431315-27434519         hsa_circ_0005633        0.009131314        0.384171219        YME1L1
  chr12:129299319-129299615       hsa_circ_0000462        0.006941025        0.380095649        SLC15A4
  chr1:118003110-118045592        hsa_circ_0002059        0.002220417        0.379882753        MAN1A2
  chr6:55966269-56006781          \#N/A                   0.022261578        0.375691727        \#N/A
  chr8:17123415-17126465          hsa_circ_0008592        0.040012263        0.373149729        VPS37A
  chr10:99915849-99923154         hsa_circ_0004419        0.032103617        0.372519687 C      10orf28
  chr20:17933230-17934761         hsa_circ_0006704        0.020560715        0.371748201        SNX5
  chr1:31532050-31532424          hsa_circ_0000045        0.040901772        0.368955101        PUM1
  chrX:14868626-14877456          hsa_circ_0006971        0.032386045        0.36887067         FANCB
  chr16:3900297-3901010           hsa_circ_0007637        0.020340132        0.36603697 C       REBBP
  chr4:103644027-103647840        hsa_circ_0006007        0.02570568         0.359726565        MANBA
  chr1:62907158-62907970          \#N/A                   0.047427014        0.35583852         \#N/A
  chr18:18619432-18624147         hsa_circ_0006733        0.037595523        0.353388689        ROCK1
  chr14:52977957-53011089         hsa_circ_0031939        0.01966747         0.351937505        TXNDC16
  chr21:37711076-37717005         hsa_circ_0001189        0.010082196        0.351308477        MORC3
  chr1:94685813-94697199          hsa_circ_0003310        0.0259611          0.351119971        ARHGAP29
  chr3:47103652-47108608          hsa_circ_0065159        0.020521933        0.350064342        SETD2
  chr8:71126137-71128999          \#N/A                   0.048201309        0.344144613        \#N/A
  chr16:71779046-71779517         hsa_circ_0002505        0.046185136        0.343484211        AP1G1
  chr5:31421378-31424578          hsa_circ_0005524        0.044966353        0.34303411         DROSHA
  chr11:1307231-1317024           hsa_circ_0008301        0.018942131        0.342187543        TOLLIP
  chr6:108242132-108243113        \#N/A                   0.012934139        0.340934595        \#N/A
  chr19:48229068-48229481         hsa_circ_0003146        0.020562164        0.340720207        EHD2
  chr3:37170553-37190529          hsa_circ_0003264        0.013154932        0.336803278        LRRFIP2
  chr7:65705311-65751696          hsa_circ_0006041        0.039282961        0.334902033        TPST1
  chr13:96409897-96416207         \#N/A                   0.0177537          0.332540513        \#N/A
  chr8:68200189-68214701          \#N/A                   0.011526157        0.328702879        \#N/A
  chr7:27668989-27689252          hsa_circ_0006773        0.003935998        0.328463848        HIBADH
  **chr10:32308785-32310215**     hsa_circ_0006408        0.043640924        0.325878207        KIF5B
  chr7:77407654-77408131          \#N/A                   0.023396605        0.323146621        \#N/A
  **chr3:56600621-56601081**      hsa_circ_0001312        0.029755856        0.321652942 CCDC   66
  chr2:234271722-234299129        \#N/A                   0.02313964         0.321131598        \#N/A
  **chr7:73100965-73101425**      hsa_circ_0005588        0.042073587        0.318524548        WBSCR22
  **chr7:72873865-72884813**      hsa_circ_0004670        0.043342921        0.316315928        BAZ1B
  **chr2:242282406-242283312**    hsa_circ_0059060        0.007810999        0.315723287        SEPT2
  **chr3:47139444-47144913**      hsa_circ_0001289        0.039274732        0.313502465        SETD2
  **chr2:43655238-43657441**      hsa_circ_0054309        0.038540875        0.309703944        THADA
  **chr21:46275124-46281186**     hsa_circ_0001200        0.0474882          0.302025085        PTTG1IP
  **chr5:179976930-179980471**    hsa_circ_0008836        0.028790905        0.292442462 C      NOT6
  **chr1:87185189-87190088**      hsa_circ_0013084        0.01567065         0.280991627        SH3GLB1
  **chr19:53577392-53578436**     hsa_circ_0007480        0.031784533        0.275005495        ZNF160
  chr16:53289511-53297009         \#N/A                   0.003705027        0.260024152        \#N/A
  **chr22:29090019-29091861**     hsa_circ_0004811        0.008438851        0.252361922 C      HEK2
  **chrX:117718697-117724265**    hsa_circ_0091382        0.032765014        0.247214419 D      OCK11
  **chr11:128993340-128997200**   hsa_circ_0005027        0.041341275        0.246885645        ARHGAP32
  **chr15:34542498-34543258**     hsa_circ_0034346        0.039707643        0.246690583        SLC12A6
  **chr10:70152894-70154208**     hsa_circ_0000239        0.008512372        0.236281903        RUFY2
  chr1:236966727-236979843        \#N/A                   0.036146024        0.222019071        \#N/A
  **chr19:33604672-33605325**     hsa_circ_0008287        0.042162087        0.207707068        GPATCH1
  **chr2:168920009-168931741**    hsa_circ_0003279        0.001767352        0.196582978        STK39
  chr1:179087721-179091002        \#N/A                   0.019369988        0.169662407        \#N/A
  **chr18:9524591-9525849**       hsa_circ_0005158        0.043392731        0.166193525        RALBP1
  **chr22:36737414-36745300**     hsa_circ_0004470        0.042494836        0.147382721        MYH9

The criteria for the differential expression were: Adjusted P\<0.05 and FC\>2 or FC\<0.5. The top 20 upregulated and downregulated genes are presented in bold. circRNA, circular RNA; FC, fold change.

###### 

Expression correlation of hsa-miR-548c-3p and its targeted genes in The Cancer Genome Atlas esophageal carcinoma cohort.

  miRNA                Gene      Correlation coefficient   FDR
  -------------------- --------- ------------------------- ----------
  hsa-miR-548c-3p      PIK3CA    −0.179442021              0.011633
  hsa-miR-548c-3p      ABL1      −0.16430793               0.021044
  hsa-miR-548c-3p      PIK3R1    −0.159510982              0.025159
  hsa-miR-548c-3p      AKT3      −0.152832805              0.032027
  hsa-miR-548c-3p C    TGF       −0.139434991              0.050682
  hsa-miR-548c-3p D    LG2       −0.136001942              0.056703
  hsa-miR-548c-3p      FRMD6     −0.128579884              0.07175
  hsa-miR-548c-3p      GAB1      −0.119111167              0.095493
  hsa-miR-548c-3p      GDF6      −0.114236586              0.109949
  hsa-miR-548c-3p      BTC       −0.114017567              0.110637
  hsa-miR-548c-3p CC   ND2       −0.113880294              0.11107
  hsa-miR-548c-3p      SOS2      −0.106454244              0.136518
  hsa-miR-548c-3p      ABL2      −0.103988246              0.14589
  hsa-miR-548c-3p      STAT5B    −0.103173372              0.149092
  hsa-miR-548c-3p      ERBB4     −0.099703628              0.163324
  hsa-miR-548c-3p C    BLB       −0.083838426              0.241477
  hsa-miR-548c-3p D    LG4       −0.083217471              0.244993
  hsa-miR-548c-3p      BMPR1A    −0.082135258              0.251205
  hsa-miR-548c-3p      PAK7      −0.079722196              0.265448
  hsa-miR-548c-3p D    LG1       −0.072417936              0.311876
  hsa-miR-548c-3p      CAMK2D    −0.070087122              0.327746
  hsa-miR-548c-3p      LEF1      −0.068131773              0.341454
  hsa-miR-548c-3p C    TNNA3     −0.06669216               0.351776
  hsa-miR-548c-3p      PAK2      −0.066482615              0.353295
  hsa-miR-548c-3p      PTK2      −0.064644262              0.366794
  hsa-miR-548c-3p      FZD1      −0.063827484              0.372892
  hsa-miR-548c-3p      NRG3      −0.053532783              0.454989
  hsa-miR-548c-3p      LATS2     −0.052315837              0.46532
  hsa-miR-548c-3p      RPS6KB1   −0.049387268              0.490702
  hsa-miR-548c-3p      NCK1      −0.047228889              0.509871
  hsa-miR-548c-3p      PRKCB     −0.045059635              0.529521
  hsa-miR-548c-3p      FZD4      −0.041762665              0.560101
  hsa-miR-548c-3p      LLGL1     −0.037399843              0.601828
  hsa-miR-548c-3p      BMPR2     −0.036025864              0.615251
  hsa-miR-548c-3p      GSK3B     −0.022579459              0.752806
  hsa-miR-548c-3p      GSK3B     −0.022579459              0.752806
  hsa-miR-548c-3p      EGFR      −0.019225787              0.788581
  hsa-miR-548c-3p      PRKCA     −0.017068489              0.811834
  hsa-miR-548c-3p      LATS1     −0.014844376              0.835982
  hsa-miR-548c-3p      FZD7      −0.012434723              0.862317
  hsa-miR-548c-3p      PAK3      −0.012235276              0.864504
  hsa-miR-548c-3p      BRAF      −0.011521175              0.872343
  hsa-miR-548c-3p      SOS1      −0.007706896              0.914404
  hsa-miR-548c-3p C    BL        −0.006374831              0.929156
  hsa-miR-548c-3p C    RKL       −0.005591422              0.937844
  hsa-miR-548c-3p      BMP5      −0.004257302              0.952654
  hsa-miR-548c-3p      EGF       0.000395288               0.995601
  hsa-miR-548c-3p      PIK3CB    0.002839251               0.968414
  hsa-miR-548c-3p      MAPK8     0.021309033               0.766301
  hsa-miR-548c-3p C    RK        0.031385585               0.661515
  hsa-miR-548c-3p      LIMD1     0.031613315               0.659213
  hsa-miR-548c-3p C    RB1       0.032804274               0.647223
  hsa-miR-548c-3p      FZD3      0.040937544               0.567885
  hsa-miR-548c-3p      PIK3R3    0.041780747               0.559931
  hsa-miR-548c-3p      KRAS      0.056284445               0.43211
  hsa-miR-548c-3p C    TNNB1     0.057967563               0.418448
  hsa-miR-548c-3p      NRAS      0.065278707               0.362099
  hsa-miR-548c-3p      CDKN1B    0.0732999                 0.306004
  hsa-miR-548c-3p      MAPK1     0.083215756               0.245003
  hsa-miR-548c-3p      EREG      0.086515941               0.226721
  hsa-miR-548c-3p      BBC3      0.102224529               0.152888
  hsa-miR-548c-3p      ELK1      0.115802515               0.105129
  hsa-miR-548c-3p      CSNK1E    0.137981222               0.053163
  hsa-miR-548c-3p      AXIN2     0.158253961               0.026346
  hsa-miR-548c-3p      FZD5      0.169685512               0.017135
  hsa-miR-548c-3p      ID2       0.202596669               0.004302
  hsa-miR-548c-3p      CTNNA2    0.246858375               0.00047

miRNA, microRNA; FDR, false discovery rate.
